Crinetics Pharmaceuticals (CRNX) EBT Margin (2017 - 2026)

Crinetics Pharmaceuticals' EBT Margin history runs 10 years deep, the most recent figure standing at 2322.28% for Q1 2026.

• On a quarterly basis, EBT Margin fell 2912948.0% year-over-year to 2322.28% in Q1 2026; TTM through Mar 2026 was 2138.26%, a 390221.0% decrease from a year earlier, with the FY2025 full-year figure at 6043.88%, up 2263158.0% from the prior year.
• EBT Margin retreated to 2322.28% in Q1 2026 per CRNX's latest filing, from 1990.5% in the prior quarter.
• Across five years, EBT Margin topped out at 26807.2% in Q1 2025 and bottomed at 90972.73% in Q3 2025.
• The 5-year median for EBT Margin is 7749.81% (2022), against an average of 1507.36%.
• Across the five-year window, EBT Margin soared 2345961 bps in 2022 and plunged 2912948 bps in 2026, its largest moves.
• Year by year, EBT Margin stood at 6345.7% in 2022, then soared by 157 bps to 16318.21% in 2023, then grew by 14 bps to 18560.15% in 2024, then plunged by 111 bps to 1990.5% in 2025, then dropped by 17 bps to 2322.28% in 2026.
• Per Business Quant, the three latest CRNX EBT Margin figures stand at 2322.28% (Q1 2026), 1990.5% (Q4 2025), and 90972.73% (Q3 2025).